正常激素性原发性甲状旁腺功能亢进是一种独特类型
该研究纳入516例因原发性甲状旁腺功能亢进接受甲状旁腺切除术的患者,分为经典组和正常激素组(高钙血症但甲状旁腺激素正常)。正常激素组占22.5%,其结石更常见、多腺体增生更多、影像学一致性更差、腺体总重量更轻,且术后2周甲状旁腺激素水平更低,但低钙血症发生率无差异。
要点
- 正常激素性甲旁亢占原发性甲旁亢的22.5%,比例高于既往报道。
- 该类型多腺体增生更常见(19.8% vs 11%),影像学一致性更差(73.2% vs 87.1%)。
- 腺体总重量更轻(531.8 mg vs 1039.6 mg),术后2周PTH更低,但低钙血症无差异。
核心结论
- 正常激素性原发性甲状旁腺功能亢进在表现、影像和术中所见上不同于经典类型,是一种独特疾病过程。
- 更多增生和更轻腺体重量使切除理想组织量具有挑战性,需长期随访研究确定最佳手术管理。
研究设计与样本
- 回顾性队列研究,纳入516例连续接受甲状旁腺切除术的原发性甲状旁腺功能亢进患者。
- 按血钙和甲状旁腺激素水平分为经典组(血钙和PTH均升高)和正常激素组(高钙血症但PTH正常)。
主要发现
- 正常激素组116例(22.5%),平均PTH 62.1 pg/mL ± 10.1、血钙10.6 mg/dL ± 0.63;经典组平均PTH 142 ± 89.0 pg/mL、血钙11.0 ± 0.88 mg/dL(均P < .01)。
- 正常激素组肾结石更常见,多腺体增生更常见(23例[19.8%] vs 44例[11%],P = .04)。
- 正常激素组影像学一致性更少(82例[73.2%] vs 337例[87.1%],P < .01),腺体总重量更轻(531.8 mg ± 680.0 vs 1039.6 mg ± 1237.3,P < .01)。
- 正常激素组术后2周PTH更低(32.5 pg/mL ± 18.95 vs 41.0 pg/mL ± 27.8,P = .01),但低钙血症(PTH <15 pg/mL)无差异(P = .93)。
临床怎么用
- 对高钙血症但PTH正常的患者应警惕正常激素性甲旁亢,术前影像可能不一致。
- 术中需注意多腺体增生可能,腺体重量较轻时切除理想组织量更具挑战性。
- 术后2周PTH可能较低,但低钙血症风险与经典类型无差异。
局限性
- 需要长期随访研究来确定最佳手术管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Normohormonal primary hyperparathyroidism presents diagnostic and intraoperative challenges, and current literature is conflicting about management. We aim to better define normohormonal primary hyperparathyroidism in order to improve the care for these patients. METHODS: In the study, 516 consecutive patients undergoing parathyroidectomy for primary hyperparathyroidism were divided into 2 groups: classic primary hyperparathyroidism (classic primary hyperparathyroidism, increased serum levels of calcium, and parathyroid hormone) and normohormonal primary hyperparathyroidism (hypercalcemia, normal serum levels of parathyroid hormone). We evaluated inter-group differences in presentation, gland weight, pathology, and complications. RESULTS: The normohormonal primary hyperparathyroidism group was comprised of 116 (22.5%) patients. Mean serum levels of parathyroid hormone and calcium were 62.1 pg/mL ± 10.1 and 10.6 mg/dL ± 0.63 in normohormonal primary hyperparathyroidism, and 142 ± 89.0pg/mL and 11.0 ± 0.88 (both P < .01) for classic primary hyperparathyroidism. Nephrolithiasis was more common in normohormonal primary hyperparathyroidism. Multigland hyperplasia was more common in normohormonal primary hyperparathyroidism 23 (19.8%) vs 44 (11%; P = .04). Concordant imaging studies were less likely in normohormonal primary hyperparathyroidism (82 [73.2%] vs 337 [87.1%; P < .01]), had a lesser total gland weight (531.8 mg ± 680.0 vs 1,039.6 mg ± 1,237.3; P < .01), and lesser 2-week parathyroid hormone (32.5 pg/mL ± 18.95 vs 41.0 pg/mL ± 27.8; P = .01). There was no difference in hypoparathyroidism (parathyroid hormone <15 pg/mL; P = .93) at 2 weeks postoperatively. CONCLUSION: Normohormonal primary hyperparathyroidism represents 22.5% of our primary hyperparathyroidism population, which is greater than reported previously. It is a distinct disease process from classic primary hyperparathyroidism in presentation, imaging, and operative findings. More hyperplasia and a lesser gland weight make it challenging to resect the ideal amount of tissue. Studies with long-term follow-up are needed to determine optimal operative management.
引用
- Applewhite MK, White MG, Tseng J, et al. Normohormonal primary hyperparathyroidism is a distinct form of primary hyperparathyroidism. Surgery. 2016. PMID: 27866715. doi:10.1016/j.surg.2016.03.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。